Erdafitinib in patients with advanced solid tumours with FGFR alterations
16589
post-template-default,single,single-post,postid-16589,single-format-standard,bridge-core-1.0.4,ajax_fade,page_not_loaded,,qode-content-sidebar-responsive,qode-child-theme-ver-1.0.0,qode-theme-ver-18.0.9,qode-theme-bridge,qode_header_in_grid,bridge-child,wpb-js-composer js-comp-ver-5.7,vc_responsive
 

Erdafitinib in patients with advanced solid tumours with FGFR alterations

Home > Blogs  > Erdafitinib in patients with advanced solid tumours with FGFR alterations

12 Aug Erdafitinib in patients with advanced solid tumours with FGFR alterations

Posted at 10:02h in Blogs by

In single-arm, phase 2 RAGNAR study, treatment with erdafitinib (selective pan-FGFR tyrosine kinase inhibitor) showed clinical benefit in the tumour-agnostic setting in patients with advanced solid tumours with susceptible FGFR alterations who have exhausted other treatment options. An objective response was observed in 64 (30% [95% CI 24–36]) of 217 patients across 16 distinct tumour types. The most commonly occurring serious treatment-related adverse events (grade 3 or higher) were stomatitis (2%) and diarrhoea (1%). (Pant S, et al. Lancet Oncol. August 2023)

No Comments

Sorry, the comment form is closed at this time.